Please ensure Javascript is enabled for purposes of website accessibility

Pfizer's Biosimilar Ruxience Gets EU Regulatory Backing

By Brian Orelli, PhD - Jan 31, 2020 at 2:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Assuming the European Commission follows the recommendation of its scientific committee, this will be the fifth oncology biosimilar from Pfizer approved in Europe.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended that the European Commission approve Pfizer's (PFE -1.40%) drug Ruxience, a biosimilar to MabThera, which to Roche (RHHBY 0.77%) and Biogen (BIIB -0.57%) sell in the U.S. as Rituxan.

CHMP's positive opinion was based on a clinical trial, dubbed Reflections B3281006, which compared Ruxience to the branded biologic drug MabThera in patients with a specific type of follicular lymphoma. Both drugs produced similar overall response rates.

Biologics are large-molecule drugs that are produced using living organisms, as opposed to via chemical processes like conventional, small-molecule medications. This difference in how they're manufactured means that while another company may be able to develop a biologic that does essentially the same thing as a previously approved drug, that new version -- the biosimilar -- will not be not quite the same as the original -- thus the "similar" in the name.

Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

While Pfizer is better known for its branded drugs, the pharmaceutical company has jumped on the biosimilar bandwagon; it has already developed four other oncology biosimilars that are available in Europe. The company sold $911 million worth of biosimilar drugs last year, with those revenues split almost equally between the U.S. and the rest of the world. Pfizer has also gotten a taste of its own medicine on this front: Sales of its anti-inflammatory biologic Enbrel were down 18% in the fourth quarter due to biosimilar competition. When Pfizer hives off its Upjohn generic drug unit later this year, its biosimilars will stay with the branded drug division.

Before Pfizer can start selling Ruxience in the EU, CHMP's positive opinion will need to be finalized by the European Commission. That decision is expected to be handed down in the first half of this year.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.96 (0.77%) $0.32
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$216.34 (-0.57%) $-1.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.